Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2009 - 2026)

Regeneron Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $8.8 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 4.84% year-over-year to $8.8 billion; the TTM figure through Mar 2026 stood at $8.8 billion (up 4.84% YoY), while the FY2025 annual figure was $8.6 billion, down 4.52% from the prior year.
• Cash & Current Investments was $8.8 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $8.6 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $10.8 billion in Q4 2023 to a low of $7.0 billion in Q3 2022.
• Historically, Cash & Current Investments has averaged $8.8 billion across 5 years, with a median of $8.8 billion in 2026.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 101.23% in 2022, then declined 23.85% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $7.7 billion in 2022, then jumped by 40.07% to $10.8 billion in 2023, then dropped by 16.9% to $9.0 billion in 2024, then slipped by 4.52% to $8.6 billion in 2025, then increased by 1.73% to $8.8 billion in 2026.
• The last three Cash & Current Investments figures came in at $8.8 billion (Q1 2026), $8.6 billion (Q4 2025), and $8.4 billion (Q3 2025), per Business Quant data.